View : 852 Download: 219

Full metadata record

DC Field Value Language
dc.contributor.author고광석*
dc.date.accessioned2016-08-29T12:08:38Z-
dc.date.available2016-08-29T12:08:38Z-
dc.date.issued2015*
dc.identifier.issn0962-9351*
dc.identifier.otherOAK-15879*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/230863-
dc.description.abstractMost chronic liver diseases (CLDs) are characterized by inflammatory processes with aberrant expressions of various pro-and anti-inflammatory mediators in the liver. These mediators are the driving force of many inflammatory liver disorders, which often result in fibrosis, cirrhosis, and liver tumorigenesis. c-Myc is involved in many cellular events such as cell growth, proliferation, and differentiation. c-Myc upregulates IL-8, IL-10, TNF-α, and TGF-β, while IL-1, IL-2, IL-4, TNF-α, and TGF-β promote c-Myc expression. Their interactions play a central role in fibrosis, cirrhosis, and liver cancer. Molecular interference of their interactions offers possible therapeutic potential for CLDs. In this review, current knowledge of the molecular interactions between c-Myc and various well known inflammatory mediators is discussed. © 2015 Ting Liu et al.*
dc.languageEnglish*
dc.publisherHindawi Publishing Corporation*
dc.titleInteractions between Myc and Mediators of Inflammation in Chronic Liver Diseases*
dc.typeReview*
dc.relation.volume2015*
dc.relation.indexSCI*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.journaltitleMediators of Inflammation*
dc.identifier.doi10.1155/2015/276850*
dc.identifier.wosidWOS:000363227600001*
dc.identifier.scopusid2-s2.0-84945313368*
dc.author.googleLiu*
dc.author.googleT.*
dc.author.googleZhou*
dc.author.googleY.*
dc.author.googleKo*
dc.author.googleK.S.*
dc.author.googleYang*
dc.author.googleH.*
dc.contributor.scopusid고광석(25027852000)*
dc.date.modifydate20240301081003*


qrcode

BROWSE